Preliminary results from LEGEND: A phase 2 study of detalimogene voraplasmid (EG-70), a novel, non-viral intravesical gene therapy for patients with BCG-unresponsive non-muscle invasive bladder cancer ...

AIM The authors investigated the safety and intraocular pressure (IOP) lowering effectiveness of trabeculectomy augmented with mitomycin C application beneath the scleral flap, and assessed the ...

Introduction Antitumor antibiotics are a class of chemotherapy drugs derived from natural sources, primarily Streptomyces bacteria, and are wid ...

UroGen's Jelmyto, a gel-based mitomycin product for LG-UTUC, achieved $25.2mn in Q3 2024, marking a 20% YoY increase. Lead candidate UGN-102 shows promise in treating low-grade intermediate risk ...

Among patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses in an analysis of the ...

PRINCETON, N.J. - UroGen Pharma Ltd. (NASDAQ: URGN), a biotech company focusing on urothelial and specialty cancer treatments with impressive gross profit margins of 90%, recently shared long-term ...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will ...

UroGen Pharma has broadened its oncology pipeline by acquiring IconOVir Bio’s assets related to the oncolytic virus ICVB-1042 ...

UGN-102 led to durable responses in low-grade, intermediate-risk bladder cancer, per phase 3 study findings at the 2025 ...

Chemoradiation with platinum-based chemo is standard for locally advanced cervical cancer, but adverse events drive ...